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Abstract
Background
Accurate information about the prevalence of Chlamydia trachomatis is needed to assess
national prevention and control measures.
Methods
We systematically reviewed population-based cross-sectional studies that estimated chla-
mydia prevalence in European Union/European Economic Area (EU/EEA) Member States
and non-European high income countries from January 1990 to August 2012. We examined
results in forest plots, explored heterogeneity using the I2 statistic, and conducted random
effects meta-analysis if appropriate. Meta-regression was used to examine the relationship
between study characteristics and chlamydia prevalence estimates.
Results
We included 25 population-based studies from 11 EU/EEA countries and 14 studies from five
other high income countries. Four EU/EEAMember States reported on nationally representa-
tive surveys of sexually experienced adults aged 18–26 years (response rates 52–71%). In
women, chlamydia point prevalence estimates ranged from 3.0–5.3%; the pooled average of
these estimates was 3.6% (95%CI 2.4, 4.8, I2 0%). In men, estimates ranged from 2.4–7.3%
PLOSONE | DOI:10.1371/journal.pone.0115753 January 23, 2015 1 / 19
OPEN ACCESS
Citation: Redmond SM, Alexander-Kisslig K,
Woodhall SC, van den Broek IVF, van Bergen J, Ward
H, et al. (2015) Genital Chlamydia Prevalence in Eu-
rope and Non-European High Income Countries: Sys-
tematic Review and Meta-Analysis. PLoS ONE 10(1):
e0115753. doi:10.1371/journal.pone.0115753
Academic Editor: David M. Ojcius, University of Cal-
ifornia Merced, UNITED STATES
Received: August 25, 2014
Accepted: November 4, 2014
Published: January 23, 2015
Copyright: © 2015 Redmond et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Our dataset as an
open access item with a Creative Commons Attribu-
tion license (CC-BY) to the Bern Open Repository
(BORIS) at http://boris.unibe.ch/id/eprint/60730.
Funding: This study was funded as part of European
Centre for Disease Prevention and Control (ECDC)
Framework Contract ECDC/2011/031, coordinated by
Marita van de Laar and Otilia Sfetcu. Otilia Sfetcu is
employed by ECDC and contributed to data interpre-
tation and preparation of the manuscript.
(pooled average 3.5%; 95%CI 1.9, 5.2, I2 27%). Estimates in EU/EEAMember States were
statistically consistent with those in other high income countries (I2 0% for women, 6% for
men). There was statistical evidence of an association between survey response rate and es-
timated chlamydia prevalence; estimates were higher in surveys with lower response rates,
(p = 0.003 in women, 0.018 in men).
Conclusions
Population-based surveys that estimate chlamydia prevalence are at risk of participation
bias owing to low response rates. Estimates obtained in nationally representative samples
of the general population of EU/EEA Member States are similar to estimates from other high
income countries.
Introduction
Surveys of the population prevalence of Chlamydia trachomatis infections (commonly known
as chlamydia) can provide information about the need for measures to prevent and control in-
fection. C. trachomatis is the most commonly reported sexually transmitted infection (STI)
and the most commonly reported of all notifiable infections in Europe and the USA [1, 2].
C. trachomatis causes infection in the lower genital tract in women and men, which can result
in upper genital tract complications and transmission of infection during pregnancy and la-
bour [3, 4]. C. trachomatis also increases susceptibility to, and infectiousness of, HIV infection
[5]. Chlamydia prevalence data for adults aged around 25 years and younger are particularly
useful for planning control measures because young adults are affected most [3]. Health au-
thorities in some European and other high income countries recommend screening in this age
group to allow both early treatment of asymptomatic infection and the prevention of long term
complications [6–9].
National surveillance data report on diagnosed cases of chlamydia infection and reported
rates vary widely; from two to 600 per 100,000 population in Europe [1]. These figures cannot
be used as estimates of population prevalence, however. Chlamydia infections are mostly
asymptomatic and rates of reported infection largely differences in levels of chlamydia testing
between countries. Cross-sectional surveys of a representative sample of the general population
(population-based surveys) [10] provide less biased estimates of the prevalence of a condition
at a particular time than surveys of attenders at health care settings. Participation bias can,
however, distort estimates of prevalence in any survey whenever there is incomplete participa-
tion [11]. Participation bias is more severe when the prevalence of the condition is low [12]
and when participation rates are low, which is likely in surveys of sensitive subjects such as sex-
ual behaviour and STI [12]. In several studies of chlamydia infection participants had higher
levels of demographic characteristics or behaviours associated with chlamydia than non-
participants [13–15], which would over-estimate prevalence.
National estimates of chlamydia prevalence in cross-sectional population-based surveys
vary considerably, even between countries with similar levels of social and economic develop-
ment [14, 16–19]. Differences in chlamydia prevalence between countries could represent real
differences in sexual behaviour patterns and chlamydia control efforts, but might also result
from variations in study design and participation rates. The primary objective of this study was
to systematically review studies reporting chlamydia prevalence in adult women and men in
the general population of the European Union and European Economic Area (EU/EEA). A
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secondary objective was to investigate the association between survey response rate and esti-
mated chlamydia prevalence in both EU/EEA and other high income countries [20].
Methods
We conducted a systematic review using a predefined protocol (S1 Text) and reported it in ac-
cordance with the guidelines on Preferred Items for the Reporting of Systematic Reviews and
Meta-Analyses (PRISMA) [21]. The study is part of a project funded by the European Centre
for Disease Control and Prevention, for which a technical report describes the results of a
group of literature reviews about chlamydia epidemiology and control [22].
Inclusion and exclusion criteria
Eligible studies designs were: cross-sectional surveys that used population-based sampling
methods and tested genital specimens from adult women and men for C. trachomatis. Studies
with the following characteristics were excluded: serological studies and studies sampling only
from extra-genital sites; participant age below 13 years; data published in letters, commentaries
and editorials. We considered the following specific groups as part of the general population:
school students if the sampling frame included all schools in the country or in a sub-national
geographic region of a country; and military recruits in countries with compulsory military
conscription.
The review focussed on adults in EU/EEA Member States at the time of the first database
search. We included the following countries to improve the generalisability of our findings and
statistical power of our analyses: non-EU/EEA countries in Europe; high income countries, as
defined by the Organisation for Economic Cooperation and Development (OECD) [20].
Data sources and searches
We searched Ovid Medline, Embase, Popline and The Cochrane Library from January 1990 to
17th October 2011 without language restrictions and updated the search on 17th August 2012.
Search strategies, adapted for each search engine, included terms for “chlamydia infection”
and “prevalence” and individual names of EU/EEA Member States, or “Europe”, or the non-
European high income countries Australia, Canada, Israel, Japan, Korea, New Zealand and
USA [20]. In addition we searched reference lists of potentially eligible studies and asked ex-
perts if they were aware of other studies. For countries with no publications identified in the
first search we then used only the country name and the free text term “chlamydia” to find fur-
ther publications. We included additional data from primary studies included in the review
even if the additional publications were published after the search deadline. S1 Text includes
the full search strategy.
Study selection
Two suitably qualified reviewers (SR, KA-K) screened the titles and abstracts of all identified
articles independently. The full text of potentially eligible studies was retrieved and two review-
ers (SR, KA-K) independently assessed each against predefined inclusion criteria. Studies were
translated where necessary. A third reviewer (NL) resolved differences between reviewers if
necessary.
Data extraction and quality assessment
Two reviewers (SR, KA-K, or SW) extracted data independently in duplicate onto standardised
piloted forms in EpiData (EpiData Association, Odense, Denmark). If multiple publications
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were associated with a study, we extracted data from the primary publication first (assigned
as the publication with the most detailed description of the survey methods). Data reported
in the primary publication were used in the case of inconsistencies. The two reviewers com-
pared the extracted data and resolved differences by discussion. If there was still a
discrepancy, a third reviewer (NL) adjudicated. We did not contact authors for additional
information.
The following information was extracted: study design; country; study population (sexually
experienced only or all participants) and setting (national or sub-national); demographic char-
acteristics; numbers eligible, invited and participating; numbers excluded with reasons; number
with C. trachomatis detected; diagnostic test method; estimated prevalence and 95% confidence
intervals (CI) reported in the study.
We used published guidelines for cross-sectional prevalence surveys to assess the risk of bias
related to methodological aspects of included studies [11]. Two reviewers (SR, KA-K, or SW)
assessed each study independently. Discrepancies were resolved by discussion or adjudication
(NL). The items assessed included: representativeness of the target and source populations;
similarity of responders and non-responders; achievement of planned sample size; use of stan-
dardised data collection methods; appropriateness of statistical methods; and response rate
[11]. We pre-specified criteria to determine whether each feature had been adequately ad-
dressed, not adequately addressed, or if there was insufficient information to decide. The guide-
line defined an adequate response rate as>80% [11]. Few studies attained this level so we also
recorded those with response rates of>60% and>70%.
Data synthesis and analysis
We analysed data for women and men separately. First, we estimated chlamydia prevalence
using the number of positive chlamydia tests and the number of people tested. Where authors
of included studies reported stratified sampling methods we used the published point estimate
and 95% CI. Where simple random sampling was done and data were available, we calculated
chlamydia prevalence (with binomial 95% CI).
We used forest plots to examine estimates of chlamydia prevalence. The I2 statistic express-
ed the percentage of variation between estimates in different studies resulting from factors
other than random variation [23]. As a guide, I2 values above 25%, 50% and 75% are suggested
as evidence of mild, moderate and severe between study heterogeneity. Low values of the I2 sta-
tistic suggest that variability between estimates is compatible with random variation [23].
Where there was evidence of moderate or severe heterogeneity, we explored reasons for this by
stratifying studies in pre-defined groups: age25 years; geographic coverage (national or sub-
national); and study population analysed (all adults or sexually experienced adults only).
Where appropriate, we pooled estimates using random effects meta-analysis to estimate the av-
erage of the study estimates and their 95% CI.
We calculated a response rate for each study, using an algorithm to define numerators and
denominators consistent with recommendations of the Council of American Survey Research
Organisations (CASRO) [24, 25]. Where available, the numerator was the number of people
providing a sample for chlamydia testing and the denominator was the number of eligible sub-
jects asked to participate, provide a sample, or sent an invitation for testing. If the study report
did not include these numbers we used the number of samples tested, followed by the number
of test results used in the analysis as the numerator and the number of eligible people as the de-
nominator. We used the published response rate in studies that used complex sampling meth-
ods and post-stratification weighting. It was not possible to calculate a response rate in studies
in which the group asked to participate is then asked if they have ever had sexual intercourse
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and chlamydia testing is restricted to those who are sexually experienced. In such studies, the
calculated response rate is underestimated.
We used meta-regression to examine the linear association between estimated chlamydia
prevalence in25 year old women and men and the calculated response rate. We applied the
sex-specific response rate for the whole study to this age group because most study reports did
not report age-specific response rates. In these analyses, the I2 statistic represents the percent-
age of heterogeneity due to factors other than sampling error after taking into account the asso-
ciation between prevalence and response rate. We also used meta-regression to analyse the
association between estimated chlamydia prevalence and the following binary variables: sex
(women versus men), age (25 years versus>25 years), geographical setting (national versus
sub-national) and response rate as reported in the included studies (<60% versus60%). We
included a term for the individual study in the model when observations from the same study
were not independent. All analyses were done using Stata statistical software (Stata 11, Stata-
Corp, Austin, Texas, USA).
Results
The search strategy gave a total of 1003 hits after de-duplication (Fig. 1). We included 25
primary studies (59 publications) in the populations of 11 EU/EEA countries [14, 16, 17, 19,
Figure 1. Flow diagram of study identification, inclusion and exclusion.
doi:10.1371/journal.pone.0115753.g001
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26–46] including Croatia, which became a Member State in July 2013 (Fig. 1) and 14 studies
(32 publications) in five non-EU/EEA countries: Switzerland [47], Australia [48–51], Canada
[52, 53], New Zealand [54] and the United States [18, 55–59]. We did not find any eligible
studies from Israel, Japan or Korea. In the included studies, 121,915 (median 953, interquartile
range 471 to 2,350) people in total were tested for chlamydia. Table 1 summarises the charac-
teristics of each study.
Twenty seven studies included women and men [14, 16–19, 26, 29–36, 41, 43, 45, 46, 48, 49,
51–54, 57–59], six included only women [27, 37–39, 50, 55] and six included only men [28, 40,
42, 44, 47, 56]. The age group ranged from 15 to 17 years in a nationally representative survey
in Germany [31] to 15 to 65 year olds in a single Arctic community in Canada [53]. Included
studies ranged from nationally representative general health [18] or sexual lifestyle [14, 16, 17,
58] surveys to studies in localised populations, designed to test the feasibility of chlamydia
screening interventions [43, 52, 54] or to get people tested and treated for chlamydia [42]. All
but two studies [38, 39] used nucleic acid amplification tests (NAAT) for chlamydia diagnosis
(Table 1) S1 Table lists the primary publication for each study and its associated publications.
Risk of bias assessment
All included studies were at risk of biases that could affect the estimated chlamydia prevalence
(S2 Table). The target population was assessed as being likely to be representative of the general
population in only 8/39 studies; six studies in EU/EEA Member States Croatia [19], France
[16], Germany [31], the Netherlands [33], Slovenia [17] and the UK [14] and two studies in
the USA [18, 58]. Seventeen studies described a comparison between participants and non-
participants. More than half of studies (23/39) did not give enough information about the
source population to determine whether this was representative of the target population.
Response rates
Authors of included studies used different denominators and numerators in their reported re-
sponse rates. We calculated a response rate according to our algorithm for all but 4/39 studies
[31, 41, 47, 51]. Amongst studies in EU/EEA countries, no study had a calculated response rate
above 80%. The highest response rate (71%) was achieved as part of a national sexual behaviour
survey in the UK [14]. Four studies had a response rate between 61% and 70% [27, 37–39]. The
lowest response rates were in studies where entire populations in large geographic areas were
invited by post; 13% in East Anglia, UK [46] and 16% in three regions in the Netherlands [34].
In non-EU countries, the calculated response rate was above 80% in two studies [53, 58], be-
tween 71% and 80% in two studies [18, 57] and between 61% and 70% in one study [55]. As
with EU/EEA Member States, the highest response rates were obtained in studies of people
who were already taking part in another study [18, 53, 57, 58].
Chlamydia prevalence estimates
Fig. 2 shows the number of people included in the analysis and overall estimate of chlamydia
prevalence for each included study. In EU/EEA countries, estimated prevalence in women
ranged from 0.2% in sexually experienced 15 to 44 year olds in Barcelona, Spain in a study of
human papillomavirus infection [37] to 8.0% in sexually experienced 21 to 23 year olds in
Aarhus County, Denmark [29] and 18 to 25 year olds in London and Avon, UK [43], who
were invited to take specimens at home in studies examining methods for chlamydia screening
(Fig. 2). For men point prevalence estimates ranged from 0.4% amongst 16 to 17 year olds tak-
ing part in a general health survey in Germany [31] to 6.9% in sexually experienced male mili-
tary recruits aged 17 to 32 years in three counties in Denmark [28] (Fig. 2). In the two studies
Chlamydia Prevalence in European and Other High Income Countries
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Table 1. Summary of characteristics of included studies.
Study name
[ref.]
National or
sub-national
study
Sex, age
in years
Whole study
sample, sexually
experienced only
Sample tested,
test used
Number invited for testing
(response rate overall, %)
Study name (acronym), if known; purpose
of study, setting and sampling strategy
EU/EEA
countries
Croatia 2011
[19]
National W&M,
18–25
Sexually
experienced only
Urine, NAAT 1005 participants
861 sexually experienced
280 provided urine sample
(women 37.5%, men 27.9%)
Cross-sectional survey of sexual behaviour
and STI prevalence. Nationally representative
sample from all 21 counties in Croatia, with
multi-stage probability sampling.
Denmark 1998
[26]
Sub-national W&M,
mean 18.0
women,
18.2 men
Sexually
experienced only
Men ﬁrst void
urine, women
urine and vaginal
ﬂush sample,
NAAT
2603 women
928 eligible (women 33.3%)
1733 men
442 eligible (men 24.8%)
RCT of home sampling versus usual care.
Random sample (half) of all high schools in
Aarhus County. All students invited. Eligible if
sexually experienced. (Only data from home
sampling group included).
Denmark 1999
[27]
Sub-national W, 20–29 Whole study
sample
Cervical swab,
NAAT
16345 eligible
11088 in cohort (women
67.8%)
Cohort study about risk factors for cervical
cancer. Random sample of women born in
Denmark, in catchment area of Righospitalet,
Copenhagen taking part in a cohort study, who
had cervical swab sample taken by
gynaecologist.
Denmark 2001
[28]
Sub-national M, 17–32 Both Urine, NAAT 2500 (men 53.8%) Cross-sectional survey to estimate chlamydia
prevalence. All men in Northern Jutland,
Aarhus or Copenhagen counties liable for
military service and seen by a medical board.
Denmark 2002
[29]
Sub-national W&M,
21–23
Sexually
experienced only
Men ﬁrst void
urine, women
vaginal ﬂush
sample, NAAT
4000 women
(women 32.5% group 1,
Response rates from online
results for 26.3% group 2)
5000 men (men 25.9%
group 1, 15.4% group 2)
RCT on effectiveness of outreach screening
strategies. Simple random sample from all
residents of Aarhus County in this age group.
Group 1 received sampling kit, group 2 had to
request kit by post.
Estonia 2008
[30]
Sub-national W&M,
18–35
Whole study
sample
Men urine,
women vaginal
swab, NAAT
1398 reachable (women
48%, men 32%)
Cross-sectional survey to estimate chlamydia
prevalence. Stratiﬁed random sample of
residents of Tartu county.
France 2010 [16] National W&M,
18–44
Sexually
experienced only
Men urine,
women vaginal
swab (or urine),
NAAT
4957 eligible by age and
sexual experience (women
54.4%, men 49.3%)
Sexual behaviour survey (subsample of
Contexte de la Sexualité en France study,
NatChla). Random subsample of sexually
experienced people from a national
population-based survey on sexual behaviour
with two-phase stratiﬁed sampling. Urine
testing kit only sent to women if no swab
returned after 1 month.
Germany 2012
[31]
National W&M,
12–17
Both Urine, NAAT 5755 in this age group
(women and men 14–17
years 63%)
General health survey (Kinder und
Jugendgesundheitsstudie, KiGGS). Two-stage
stratiﬁed cluster sampling, nationally
representative sample of 0–17 year olds. Only
tested samples from participants in this age
group.
Netherlands
2000 [32]
Sub-national W&M,
15–40
Whole study
sample
First void urine,
NAAT
5714 women (women
50.8%)
5791 men (men 33.0%)
Cross-sectional survey to estimate chlamydia
prevalence and screening feasibility. Simple
random sample of patients on the lists of 16
general practices in Amsterdam.
Netherlands
2005 [33]
National W&M,
15–29
Both Urine, NAAT 20791 (women 47.0%, men
33.0%)
Cross-sectional survey to estimate chlamydia
prevalence and screening feasibility (CT
PILOT). Stratiﬁed probability sample of
randomly selected men and women in 4
regions of the Netherlands according to
population density. Regions not sampled at
random.
Netherlands
2010 [34]
Sub-national W&M,
16–29
Sexually
experienced only
Men urine,
women vaginal
swab or urine,
NAAT
140058 Amsterdam (women
22.4%, men 10.8%)
107806 Rotterdam (women
19.6%, men 10.5%)
Cluster controlled trial of chlamydia screening
effectiveness (Chlamydia Screening
Implementation, CSI). All 16–29 year old
residents of Amsterdam, Rotterdam, parts of
South Limburg. Sexually active people invited
to request test kit. South Limburg excluded
because eligibility depended on response to
questionnaire assessing risk of chlamydia.
(Continued)
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Table 1. (Continued)
Study name
[ref.]
National or
sub-national
study
Sex, age
in years
Whole study
sample, sexually
experienced only
Sample tested,
test used
Number invited for testing
(response rate overall, %)
Study name (acronym), if known; purpose
of study, setting and sampling strategy
Norway 2005
[35]
Sub-national W&M,
18–29
Whole study
sample
Urine, NAAT 646 reached (women
43.8%, men 25%)
Cross-sectional survey to estimate chlamydia
prevalence. All patients on the list of a group
practice in Oslo.
Norway 2012
[36]
Sub-national W&M,
18–25
Sexually
experienced only
Urine, NAAT 10000 invited
1670 returned sample
(women 18.9%, men 11.9%)
Cross-sectional survey to estimate chlamydia
prevalence. Simple random sample of 10,000
people in this age group living in Rogaland
county using unique personal identiﬁcation
number.
Slovenia 2004
[17]
National W&M,
18–49
Both First void urine,
NAAT
2616 invited (women 60.0%,
men 50.9%)
Sexual behaviour study. Stratiﬁed two stage
probability sample of the general population of
Slovenia in this age group. All participants
invited to provide specimen for chlamydia
testing.
Spain 2007 [37] Sub-national W, 15–44 Sexually
experienced only
Cervical swab,
NAAT
1821 invited
916 reached or accepted
(women 66.1%)
Cross-sectional multinational HPV prevalence
survey. Random age stratiﬁed sample of the
adult female general population from census
list of 4 urban communities in metropolitan
Barcelona.
Sweden 1992
[38]
Sub-national W, 15–34 Sexually
experienced only
Cervical and
urethral swabs,
EIA ( direct IF)
543 reached and were
sexually experienced
women (68.9%)
Cross-sectional survey to estimate chlamydia
prevalence. All women in this age group in a
primary health care area in Nättraby invited,
only sexually experienced screened.
Sweden 1995
[39]
Sub-national W, 19, 21,
23, 25
Whole study
sample
Cervical and
urethral swabs,
culture
816 reached
611 participated (68.3%
women)
Cross-sectional survey to estimate chlamydia
prevalence. All women of this age living in
primary health care area of Ålidhem
community centre in Umeå.
Sweden 2003
[40]
Sub-national M, 22 Whole study
sample
First void urine,
NAAT
1074 (men 35.6%) Cross-sectional survey to investigate feasibility
of chlamydia screening. All males of this age
living in Umeå.
Sweden 2004
[41]
Sub-national W&M,
20–24
Whole study
sample
First void urine,
NAAT
200 (women 65%, men
45%)
Cross-sectional survey to estimate chlamydia
prevalence and cost-effectiveness of home
sampling. Simple random sample of 100 men
and 100 women in this age group living in
Umeå.
Sweden 2007
[42]
Sub-national M, 19–24 Whole study
sample
First void urine,
NAAT
1936 reached (men 14.5%) Cross-sectional survey to estimate chlamydia
prevalence. Sampling method unclear, 1000
men living in Uppsala county (from population
register), and 1000 Uppsala university
students (from student register database).
United Kingdom
2000a [44]
Sub-national M, 18–35 Whole study
sample
First pass urine,
NAAT
919 invited by post and
reachable (men 45.3%)
Cross-sectional survey to estimate chlamydia
prevalence and screening feasibility. Postal
recruitment of all men aged 18–24 and a
random sample of men aged 25–35 in 4
general practices in North West London.
United Kingdom
2000b [43]
Sub-national W&M,
18–35
Sexually
experienced only
Men urine,
women urine or
vulval swab,
NAAT
166 women reached
(women 39%)
175 men reached (men
46%)
Pilot study of acceptability of home sampling.
Simple random sample of patients on the lists
of 3 general practices in North West London
and Avon. Urine samples from random 50% of
women, vulval swabs from other 50%.
United Kingdom
2001 [14]
National W&M,
18–44
Sexually
experienced only
Urine, NAAT 5026 invited to give urine
sample (women 71.1%, men
68.7%) a
Sexual behaviour study (National Survey of
Sexual Attitudes and Lifestyles, Natsal-2).
Random sample of sexually experienced
people taking part in a stratiﬁed probability
sample of people aged 16–44 years resident
in the United Kingdom (total 11 161
interviewed).
United Kingdom
2007 [45]
Sub-national W&M,
16–39
Whole study
sample
Men ﬁrst void
urine, women
ﬁrst void urine
and vulvo-
vaginal swab,
NAAT
14382 reached (women
37.6%, men 27.9%)
Cross-sectional survey to estimate chlamydia
prevalence and screening feasibility
(Chlamydia Screening Studies project, ClaSS).
Random sample of general population in
Birmingham and Bristol areas, selected from
27 general practice lists.
(Continued)
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Table 1. (Continued)
Study name
[ref.]
National or
sub-national
study
Sex, age
in years
Whole study
sample, sexually
experienced only
Sample tested,
test used
Number invited for testing
(response rate overall, %)
Study name (acronym), if known; purpose
of study, setting and sampling strategy
United Kingdom
2012 [46]
Sub-national W&M,
18–24
Whole study
sample
Urine, NAAT 29917 invited (women
13.2%, men 9.8%)
Cross-sectional survey investigating feasibility
of postal screening invitations. All people in
this age group registered with any GP in North
East Essex Primary Care Trust.
Non-EU/EEA
countries,
Europe
Switzerland
2008 [47]
Sub-national M, 18–26 Both First void urine,
NAAT
521 eligible and gave written
consent (insufﬁcient data to
calculate)
Cross-sectional survey to estimate chlamydia
prevalence. All young Swiss men attending
obligatory medical board before army
recruitment (French speaking region only).
Non-EU/EEA
countries, high
income OECD
Australia 2003
[48]
Sub-national W&M,
15–40+
Whole study
sample
First catch urine,
NAAT
6431 eligible
2862 participated (women
and men 43.8%)
General health survey. All people living in 26
rural indigenous Australian and Torres Strait
Islander communities in northern Queensland
taking part in Well Person’s Health Check.
Australia 2004
[49]
Sub-national W&M,
15–35
Whole study
sample
Men ﬁrst void
urine, women
vaginal swab,
NAAT
2703 eligible listed
1219 screened (women
50.7%, men 39.3%)
Cross-sectional survey to estimate chlamydia
and gonorrhoea prevalence. Indigenous
Australian people aged 15–35 living in Alice
Springs area
Australia 2006
[50]
Sub-national W, 18–35 Both First void urine,
NAAT
1532 eligible households
979 women interviewed
657 gave urine sample
(women 42.9%)
Cross-sectional survey to estimate chlamydia
prevalence. Simple random sample from
Melbourne residential telephone directory.
Australia 2008
[51]
Sub-national W&M,
14–40
Whole study
sample
Men ﬁrst void
urine, women
low vaginal
swabs, NAAT
ca. 1300 in 1996
(insufﬁcient data to
calculate)
Cross-sectional survey in STI control
programme screening for chlamydia,
gonorrhoea and syphilis. All resident
indigenous Australians living in the Anangu
Pitjantjatjara Yankunytjatjara Lands.
Canada 2002
[52]
Sub-national W&M,
15–39
Whole study
sample
First catch urine,
NAAT
1075 women (women
29.3%)
1130 men (men 16.2%)
Chlamydia mass screening study. All adults
from remote Inuit communities in Nunavik
region. All sexually experienced or in this age
group especially encouraged to take part.
Canada 2009
[53]
Sub-national W&M,
15–65
Whole study
sample
Urine, NAAT 224 estimated eligible
(insufﬁcient data to
calculate)
181 screened (80.8% for
women and men)
Chlamydia and gonorrhoea mass screening
study. All men and women in this age group
living in a rural Inuit community from Bafﬁn
Region, Nunavut.
New Zealand
2002 [54]
Sub-national W&M, 16+ Sexually
experienced only
Urine, NAAT 1582 invited
1136 consented
582 sexually active
(insufﬁcient data to
calculate)
Cross-sectional survey to estimate chlamydia
prevalence. Random sample of 50% of
classes in all private and public high schools,
Christchurch. Only sexually active had their
samples tested.
USA 2001 [55] Sub-national W, 18–29 Sexually
experienced only
Urine, NAAT 2148 eligible
1439 enrolled
1370 tested
1314 sexually active
(women 61.2%)
Household survey of risk behaviour and
chlamydia prevalence. All English- or Spanish-
speaking women in this age group in a
random sample of low income housing blocks
from the 1990 census (<10th percentile) in 3
counties in California.
USA 2002a [56] National M, 18–19,
22–26
Whole study
sample
Urine, NAAT 1995 survey: data from 470
aged 18–19, and 995 aged
22–26 who were aged 15–
19 in 1988 survey
(insufﬁcient data to
calculate)
National Surveys of Adolescent Males
(NSAM). Sexual health survey. Nationally
representative sample of never-married, non-
institutionalised men aged 15–19 (1995
survey), and aged 22–26 (aged 15–19 in 1988
survey but re-interviewed in 1995).
Oversampling of black and Hispanic youths.
(Continued)
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that included only teenagers [26, 31], estimates were lower in men than in women (2.6%
vs. 5.0% in Denmark, 0.4% vs. 2.1% in Germany). In non-EU/EEA countries, estimated preva-
lence in women ranged from 0.9% in 18 to 35 year olds in Melbourne, Australia [50] to 13.8%
in a Canadian Arctic community aged 18 to 65 years [32] (Fig. 2). In men, the lowest estimated
prevalences were in 14 to 39 year olds in a general health survey in the USA (1.1% [18]) and
military recruits aged 18 to 26 years in the French-speaking region of Switzerland (1.2% [47]).
The highest estimate was from 15 to 39 year olds in a remote community in Queensland, Aus-
tralia (10.6% [48]).
Fig. 3 and Fig. 4 show chlamydia prevalence estimates from studies conducted in EU/EEA
and other high income OECD countries among women and men aged26 years. In nationally
representative samples of sexually experienced people in five countries, there was no or only
mild heterogeneity. In women, estimates ranged from 3.0% (95% CI 1.7–5.0%) in the UK [14]
to 5.3% (95% CI 2.3, 10.2%) in Croatia [19]. The pooled average estimate in all five countries
was 4.3% (95% CI 3.6, 5.0%, I2 0%) (Fig. 3) and in the four EU/EEAMember States 3.6% (95%
CI 2.4, 4.8%, I2 0%, not shown in the figure). In men, estimates ranged from 2.4% (95% CI 1.0,
5.7%) in France [16] to 7.3% (95% CI 3.4, 13.4%) in Croatia [19]. The pooled average estimate
in all five countries was 3.6% (95% CI 2.8, 4.4%, I2 6%) (Fig. 4) and in the four EU/EEA Mem-
ber States 3.5% (95% CI 1.9, 5.2%, I2 27%, not shown in the figure). Heterogeneity was severe
(I2>75%) in sub-national studies and in nationally representative studies with chlamydia
prevalence estimates for the whole study population in both women and men; we did not esti-
mate pooled averages for these groups of studies (Fig. 3 and Fig. 4).
There was statistical evidence of an association between overall sex-specific survey response
rate and estimated chlamydia prevalence in both women and men; estimated chlamydia preva-
lence was higher in surveys with lower response rates (Fig. 5, women, P = 0.003; men, P = 0.018
from meta-regression). Results were similar if the analysis was restricted to studies that re-
ported age-specific response rates for women and men aged25 years (women, 15 studies,
I2 80.6%, P = 0.004; men, 13 studies, I2 88.6%, P = 0.04). When the variable response rate was
Table 1. (Continued)
Study name
[ref.]
National or
sub-national
study
Sex, age
in years
Whole study
sample, sexually
experienced only
Sample tested,
test used
Number invited for testing
(response rate overall, %)
Study name (acronym), if known; purpose
of study, setting and sampling strategy
USA 2002b [57] Sub-national W&M,
18–35
Whole study
sample
Urine, NAAT 1224 adults aged 18–45
reached
728 age-eligible for
screening (women and men
79.5%)
Cross-sectional survey to estimate chlamydia
and gonorrhoea prevalence. Stratiﬁed
probability sampling of households in
Baltimore; urine samples requested from those
in study age group.
USA 2004 [58] National W&M, 18–
26
Both First void urine,
NAAT
Wave III: 14322 (women
and men 84%)
Cohort study (US National Longitudinal Study
of Adolescent Health, Add Health). Nationally
representative sample of young people in the
USA. Total in ﬁrst survey, Wave I: 18924.
USA 2011 [59] Sub-national W&M, 15–
35
Both Urine, NAAT 4998 eligible (women and
men 42.7%)
Cross-sectional survey to estimate STI
prevalence (Monitoring STI Survey Program).
Probability sample of Baltimore residents.
USA 2012 [18] National W&M, 14–
39
Whole study
sample
Urine, NAAT 20836 selected
17190 interviewed (women
80.4%, 2007–2008, men
74.5%, 2007–2008) b
General health survey (US National Health
and Nutrition Examination Surveys, NHANES).
Stratiﬁed multistage probability cluster
sampling. Data from ﬁve 2-year survey cycles.
Abbreviations: EIA, enzyme immunoassay test; EU/EEA, European Union or European Economic Area Member States; IF, immunoﬂuorescence test; M,
men; NAAT, nucleic acid ampliﬁcation test; OECD, Organization for Economic Cooperation and Development; STI, sexually transmitted infections; W: women.
a Numbers from technical report Erens et al. 2001 [24].
b Response rates from online results for 2007–2008 http://www.cdc.gov/nchs/nhanes/response_rates_CPS.htm.
doi:10.1371/journal.pone.0115753.t001
Chlamydia Prevalence in European and Other High Income Countries
PLOS ONE | DOI:10.1371/journal.pone.0115753 January 23, 2015 10 / 19
dichotomised (<60% and60%), the ratio of odds for chlamydia infection was 1.9 times
higher in studies with response rates<60% than in studies with response rates60%.
After controlling for national or sub-national study coverage, the ratio of odds was 1.7 (95%
CI 0.9–3.2, P = 0.081). There was no strong evidence of an association between estimated chla-
mydia prevalence and response rate in surveys of nationally representative population samples
Figure 2. Forest plot, overall estimate of chlamydia prevalence in women andmen of all ages in EU/
EEA and other high-income OECD countries in all included studies. CI, confidence interval. The small
filled diamond shows the point estimate, the lines either side are the 95% CI. Each row is a study or group
within a study, with separate estimates from women and men, where available. In Denmark 2002, Group 1
received home sampling kits, Group 2 had to request a sampling kit by post. In USA 2012, separate
estimates are reported for five survey cycles of the National Health and Nutrition Surveys. In Netherlands
2010, separate estimates were reported separately for Amsterdam and Rotterdam.
doi:10.1371/journal.pone.0115753.g002
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Figure 3. Forest plot, estimates of chlamydia prevalence in women 26 years in EU/EEA and other
high-income OECD countries. CI, confidence interval. The small filled diamond shows the point estimate,
the lines either side are the 95% CI. Each row is a study or group within a study. In Denmark 2002, Group 1
received home sampling kits, Group 2 had to request a sampling kit by post. Estimates are shown separately
for sexually experienced participants only or for the overall sample, in either national or sub-national
populations.
doi:10.1371/journal.pone.0115753.g003
Figure 4. Forest plot, estimates of chlamydia prevalence in men 26 years in EU/EEA and other high-
incomeOECD countries. CI, confidence interval. The small filled diamond shows the point estimate, the
lines either side are the 95% CI. Each row is a study or group within a study. In Denmark 2002, Group 1
received home sampling kits, Group 2 had to request a sampling kit by post. Estimates are shown separately
for sexually experienced participants only or for the overall sample, in either national or sub-national
populations.
doi:10.1371/journal.pone.0115753.g004
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in women (P = 0.644, Fig. 6A) or men (P = 0.729, Fig. 6B). In sub-national surveys, the meta-
regression plot suggests an association between estimated chlamydia prevalence and with re-
sponse rate (Fig. 6A and Fig. 6B). There was statistical evidence of this association in women
(P = 0.063) but not men (P = 0.267) and there was substantial residual heterogeneity between
prevalence estimates (I2 91% women, 81% men). The regression lines for subnational and na-
tional surveys approached each other at higher levels of response rates. This suggests that at
very high response rates, estimated prevalence would be similar in both survey types.
Discussion
Main findings
In this systematic review we found population-based surveys estimating chlamydia prevalence
from 11 EU/EEA Member States, one non-EU/EEA European countries and four other high
income countries. In nationally representative samples of sexually experienced26 year olds,
between study heterogeneity was low in women (five studies, range 3.0%, 95% CI 1.7, 5.0% in
UK to 5.3%, 95% CI 2.3, 10.2% in Croatia, pooled estimate 4.3%, 95% CI 3.6, 5.0%, I2 0%) and
men (five studies, range 2.4%, 95% CI 1.0, 5.7% in France to 7.3%, 95% CI 3.4, 13.4% in Croa-
tia, pooled estimate 3.6%, 95% CI 2.8, 4.4%, I2 6.2%). Chlamydia prevalence estimates from
population-based surveys conducted in sub-national population samples were very heteroge-
neous, ranging from 0.6% to 10.7% in women and 1.1% to 5.9% in men aged25 years. Re-
sponse rates in most included studies were<60%. There was statistical evidence of an inverse
association between survey response rate and chlamydia prevalence estimates in both women
(P = 0.003) and men (P = 0.018).
Strengths and weaknesses of the review
Strengths of this review are the broad and inclusive search strategy and the detailed assessment
of study methodology. We think that we are unlikely to have missed any large published arti-
cles, but might not have found all unpublished data. Our systematic searches covered studies
published until August 2012. Since then, we identified one additional large survey of the UK
population in 2010 to 2011 [60], which used methods similar to those of a survey from 1999 to
2000 [14]. Overall response rates and estimates of chlamydia prevalence were similar in both
Figure 5. Meta-regression analysis of chlamydia prevalence estimates in women andmen aged25
years against calculated sex-specific response rate for all women andmen in the study, in EU/EEA
and other high-income OECD countries. The size of the open circle corresponds to the precision of the
prevalence estimate. n = number of studies. For women, n = 27, P = 0.003, I2 82.4%; men, n = 18, P = 0.018,
I2 87.6%.
doi:10.1371/journal.pone.0115753.g005
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surveys. Another strength is that we only included studies that used population-based sampling
methods to obtain estimates of chlamydia prevalence in the general population. Previous sys-
tematic reviews have included studies done in health care settings [1, 61, 62], the results of
which cannot be easily extrapolated to the general population because they include people with
symptoms and exposures that put them at higher than average risk of chlamydia infection. The
inclusion of data from countries outside Europe increased statistical power to examine hetero-
geneity and allowed us to examine the generalisability of our findings to countries with similar
levels of social and economic development. There was some inconsistency in the countries in-
cluded in the review, however. Bulgaria, Hungary, Romania are EUMember States but not
high-income economies; other high-income EU/EEA economies are not OECD members (Cy-
prus, Latvia, Liechtenstein, Lithuania, Malta). We did not find population-based studies in any
of these countries. Two main limitations of the review relate to the small number of studies
Figure 6. Meta-regression analysis of chlamydia prevalence estimates in participants of all ages
against response rate, by national or sub-national study design. Panel A, women; Panel B, men. The
size of the open circle corresponds to the precision of the prevalence estimate. n = number of studies.
For women, national studies, n = 10, P = 0.644, I2 46.8%; sub-national studies, n = 18 studies, P = 0.063,
I2 91.23%; for men, national studies, n = 10, P = 0.729, I2 57.56%; sub-national studies, n = 15 studies,
P = 0.267, I2 81.25%.
doi:10.1371/journal.pone.0115753.g006
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with comparable data and the completeness of the data reported. First, we could not calculate a
consistent response rate for all studies because of differences between studies in the data re-
ported and differences in study design. We overcame this limitation in part by applying an al-
gorithm to select the numerator and denominator that were closest to the recommended
definition [24]. The recommended numerator and denominator cannot be applied, however,
in study designs that enrol participants and then restrict chlamydia testing to responders re-
porting sexual experience. In this case, the calculated response rate underestimates the true re-
sponse rate and cannot be corrected unless the percentages excluded because they have not had
sexual experience are recorded. Second, four countries (Denmark, Netherlands, Sweden, UK)
accounted 17/25 included studies from EU/EEA countries. The small number of countries con-
tributing to the review needs to be considered when interpreting the findings.
Interpretation
Estimates of chlamydia prevalence in women and men aged26 years in surveys of nationally
representative samples of populations in EU/EEA and other high income countries were statis-
tically consistent and between study variability was compatible with random variation [23].
The pooled estimates for EU/EEA Member States are the average of estimates of chlamydia
prevalence from four studies and do not mean that this is the chlamydia prevalence across Eu-
rope. The chlamydia prevalence estimates and their precision need to be interpreted in the con-
text of national differences in culture, sexual behaviours and attitudes, health systems and
intensity and duration of chlamydia control activities [63, 64]. Most of the point estimates of
chlamydia prevalence were<5% in both women and men. Participation bias might still affect
these estimates because of low response rates and the low estimated prevalence of chlamydia
[12]. Over-estimation is more likely than under-estimation because responders have higher
levels of factors associated with STI than non-responders [14].
In cross-sectional surveys of chlamydia prevalence, the lower the calculated response rate
the higher was the estimated prevalence. The association appeared to be more marked in stud-
ies conducted in sub-national regions of a country than in nationally representative population
surveys (Fig. 6). Differences in the objectives of studies in these groups could help explain this
finding. The objectives of sub-national studies were diverse. Studies that assessed the feasibility
of chlamydia screening approaches might have specifically encouraged chlamydia testing by
people at high risk of infection but have low overall response rates [29, 34, 45]. Studies designed
to measure chlamydia prevalence as a main [50] or subsidiary objective [37] might have en-
rolled a more representative sample of the target population. In nationally representative sur-
veys, chlamydia testing was done as a small part of studies that were designed to measure a
wide range of health-related [58] or sexual health-related behaviours [14, 16, 17]. These studies
tended to have higher overall response rates than sub-national studies. Of note, the national
survey with the highest estimate of chlamydia prevalence, in Croatia, also had the lowest re-
sponse rate [19].
Implications for practice, policy and research
This review highlights several challenges to determining accurate and comparable estimates of
chlamydia prevalence between countries. Standard definitions used by survey and market re-
search organisations to define target and study populations and to calculate response rates
were rarely adhered to. Reporting standards for prevalence surveys in epidemiological research,
perhaps as an extension to existing Standards for the Reporting of Observational Studies in
Epidemiology [65] might help to improve consistency in future. The association between esti-
mated chlamydia prevalence and survey response rate suggests that estimates from studies
Chlamydia Prevalence in European and Other High Income Countries
PLOS ONE | DOI:10.1371/journal.pone.0115753 January 23, 2015 15 / 19
with very low response rates should not be interpreted as estimates of the population chlamyd-
ia prevalence, even when sampling has covered a whole defined region of a country. This re-
view does not provide data to specify a threshold response rate below which the value
estimated is unreliable, however. Our review shows that population-based chlamydia preva-
lence has been estimated in a minority of European and other high income countries. Surveys
among samples representative of national populations in a wider variety of countries, particu-
larly in non-high income EUMember States, and in other low and middle income countries
would be valuable if they use consistent methods and achieve high response rates. Surveys that
estimate chlamydia prevalence are at risk of participation bias owing to low response rates; esti-
mates obtained in nationally representative samples of the general population of EU/EEA
Member States are similar to estimates from other high income countries.
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